Overall, there is a general consensus that we have to be cautions as to consider RTN4 as a specific biomarker for ALS, thus questioning whether this protein could be a possible candidate target for novel drugs against the disease (Tågerud et al. 2007). Here, RTN4 is linked to amyotrophic lateral sclerosis.